Advanced Search

Submit Manuscript



Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults

Xiaoqiang Liu1,† , Yuhua Li2,† , Zhongfang Wang3,† , Shouchun Cao2,† , Weijin Huang2,† , Lin Yuan4,† , Yi-Jiao Huang5 , Yan Zheng1 , Jingjing Chen4 , Bo Ying6 , Zuoyun Xiang4 , Jin Shi4 , Jincun Zhao3,* , Zhen Huang4,* , Cheng-Feng Qin5,7,*

1Yunnan Province Centre for Disease Control and Prevention, Kunming, Yunnan, China
2National Institutes for Food and Drug Control, Beijing, China
3Respiratory Medicine, Guangzhou Institute of Respiratory Health, Guangzhou, Guangdong, China
4Walvax Biotechnology Co., Ltd., Kunming, Yunnan, China
5State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China
6Suzhou Abogen Biosciences Co., Ltd, Suzhou, Jiangsu, China
7Research Unit of Discovery and Tracing of Natural Focus Diseases, Chinese Academy of Medical Sciences, Beijing, China
These authors contributed equally: Xiaoqiang Liu, Yuhua Li, Zhongfang Wang, Shouchun Cao, Weijin Huang, Lin Yuan
* Correspondence: Jincun Zhao( Huang( Qin(

Dear Editor,

To May 2022, the COVID-19 pandemic has claimed more than 6.28 million lives, with more than 524 million confirmed cases worldwide. The recent emergence of highly transmissible Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered another major surge in both confirmed cases and deaths.1 Ten COVID-19 vaccines have been approved by the World Health Organization (WHO) for emergency use, including the two mRNA vaccines, BNT162b2 and mRNA-1273, and two Chinese inactivated vaccines, CoronaVac and BBIBP-CorV. However, the rapid waning of vaccine-induced virus-neutralizing antibody titers and the continuous emergence of variants of concern (VOCs), including Alpha, Beta, Delta and Omicron, have created unprecedented challenges in the eradication of COVID-19 pandemic.2,3,4


Browse 89